Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 21 Dec 2020
Expanded PBS access to breakthrough medicine for lung cancer
20 December 2020 - A significant lung cancer treatment option that costs approximately $88,000 a year will soon be available for ...
Posted by Michael Wonder on 21 Dec 2020
U.S. FDA approves supplemental new drug application for Takeda’s Iclusig (ponatinib) for adult patients with resistant or intolerant chronic phase CML
19 December 2020 - Approval based on data from the Phase 2 OPTIC trial, which evaluated response-based Iclusig dosing regimens in ...
Posted by Michael Wonder on 21 Dec 2020
The EU price list for COVID-19 vaccines was leaked. Will Canada release its prices?
18 December 2020 - The office of Canada’s minister in charge of procuring its stockpile of the coronavirus vaccine said ...
Posted by Michael Wonder on 21 Dec 2020
Newly approved treatment could save a young child in Edmonton with a rare disease. It costs 2.8 million dollars per dose.
19 December 2020 - Reign Johnston is a happy baby who enjoys painting as much as playing with toys. His green ...
Posted by Michael Wonder on 21 Dec 2020
Closure of the post-market review of the use of biologics in the treatment of severe chronic plaque psoriasis
21 December 2020 - A plain language summary for the post-market review of the use of biologics in the treatment ...
Posted by Michael Wonder on 20 Dec 2020
Hikma launches generic Advair Diskus following FDA approval
17 December 2020 - Hikma Pharmaceuticals announces it has received FDA approval for and launched its generic version of GlaxoSmithKline’s ...
Posted by Michael Wonder on 20 Dec 2020
Swiss to start Pfizer COVID-19 vaccine jabs after watchdog's OK
19 December 2020 - Switzerland will start getting doses of COVID-19 vaccine from Pfizer and partner BioNTech within days after ...
Posted by Michael Wonder on 20 Dec 2020
Lung cancer drug subsidy will make 'big difference' for patients
20 December 2020 - If you’re a non-smoking woman and you develop a cough, the last thing you think you've ...
Posted by Michael Wonder on 19 Dec 2020
Karyopharm announces FDA approval of Xpovio (selinexor) as a treatment for patients with multiple myeloma after at least one prior therapy
18 December 2020 - Oral Xpovio now available as a treatment option for patients with multiple myeloma as early as first ...
Posted by Michael Wonder on 19 Dec 2020
FDA takes additional action in fight against COVID-19 by issuing emergency use authorisation for second COVID-19 vaccine
18 December 2020 - Action follows thorough evaluation of available safety, effectiveness, and manufacturing quality information by FDA career scientists, input ...
Posted by Michael Wonder on 18 Dec 2020
Novartis receives complete response letter from U.S. FDA for inclisiran
18 December 2020 - The U.S. FDA has not raised any concerns related to the efficacy or safety of inclisiran. The ...
Posted by Michael Wonder on 18 Dec 2020
FDA approves first adjuvant therapy for most common type of lung cancer
18 December 2020 - Today, the U.S. FDA approved Tagrisso (osimertinib) as the first adjuvant treatment for patients with non-small cell ...
Posted by Michael Wonder on 18 Dec 2020
Medicines for hepatitis C remain in the high-cost protection after TLV's reconsideration
18 December 2020 - During the autumn, the Swedish Dental and Pharmaceutical Benefits Agency, TLV, reconsidered the subsidy of the hepatitis ...
Posted by Michael Wonder on 18 Dec 2020
FDA approves first oral hormone therapy for treating advanced prostate cancer
18 December 2020 - Today, the U.S. FDA approved Orgovyx (relugolix) for the treatment of adult patients with advanced prostate cancer. ...
Posted by Michael Wonder on 18 Dec 2020
Novaremed receives fast track designation from the FDA for NRD135S.E1 for the treatment of painful diabetic peripheral neuropathy
18 December 2020 - Novaremed announced today that it has received fast track designation from the U.S. FDA for the development ...